Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting

Cancer cells deficient in BRCA1 or BRCA2 function hyper-sensitive to APTO-253

Cancer cells deficient in BRCA1 or BRCA2 function hyper-sensitive to APTO-253

Share this post